MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$268,295K
Net Income
$18,348K
Net Profit Margin
6.84%
EPS
$0.15
Unit: Thousand (K) dollars
Revenue Breakdown
Syfovre
Licensing And Other Revenue
Empaveli Pegcetacoplan
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
268,295
199,913
458,578
178,494
Cost of sales
40,547
29,719
24,531
13,626
Research and development
76,958
74,233
68,186
67,015
Selling, general and administrative
124,323
147,103
142,678
131,139
Total operating expenses
241,828
251,055
235,395
211,780
Net operating income/(gain)
26,467
-51,142
223,183
-33,286
Interest income
2,914
3,502
4,376
2,607
Interest expense
10,317
10,847
11,279
11,152
Other income/(expense), net
88
-151
37
146
Net income/(gain) before taxes
19,152
-58,638
216,317
-41,685
Income tax expense
496
313
602
466
Net income/(gain)
18,656
-58,951
215,715
-42,151
Unrealized loss/(gain) on pension plans
-
30
-137
-
Foreign currency translation
-308
327
32
485
Total other comprehensive income/(loss)
-308
297
169
485
Comprehensive income/(gain), net of tax
18,348
-58,654
215,884
-41,666
Basic EPS
0.15
-0.463
1.71
-0.33
Diluted EPS
0.15
-0.425
1.67
-0.33
Basic Average Shares
127,682,000
126,679,000
126,424,000
126,024,000
Diluted Average Shares
131,424,000
137,876,000
130,067,000
126,024,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Syfovre
$150,719K
(15.78%↑ Y/Y)
Empaveli Pegcetacoplan
$41,291K
(109.32%↑ Y/Y)
Product
$192,010K
(28.09%↑ Y/Y)
Licensing And Other
Revenue
$76,285K
(351.47%↑ Y/Y)
Revenue
$268,295K
(60.85%↑ Y/Y)
Net operating
income/(gain)
$26,467K
(131.76%↑ Y/Y)
Interest income
$2,914K
(9.63%↑ Y/Y)
Other
income/(expense), net
$88K
(153.33%↑ Y/Y)
Total operating
expenses
$241,828K
(-3.32%↓ Y/Y)
Net income/(gain)
before taxes
$19,152K
(120.84%↑ Y/Y)
Interest expense
$10,317K
(-6.63%↓ Y/Y)
Selling, general and
administrative
$124,323K
(-3.88%↓ Y/Y)
Research and development
$76,958K
(-10.95%↓ Y/Y)
Cost of sales
$40,547K
(18.01%↑ Y/Y)
Net income/(gain)
$18,656K
(120.23%↑ Y/Y)
Income tax expense
$496K
(45.45%↑ Y/Y)
Comprehensive income/(gain),
net of tax
$18,348K
(119.95%↑ Y/Y)
Total other
comprehensive income/(loss)
-$308K
(-221.26%↓ Y/Y)
Foreign currency
translation
-$308K
(-221.26%↓ Y/Y)
Buy us a coffee
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)